Testing SMZ1 with ranibizumab for wet macular degeneration
Part of Eyes & vision clinical trials.
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 50 years old or older.
- You have a type of wet macular degeneration (nAMD) that is actively leaking, but you do not have a specific subtype called PCV.
- The scar tissue in your eye covers less than half of the affected area.
- Your vision in the study eye must be between 20/40 and 20/320 (on a standard eye chart).
- You have not had any previous eye treatments for wet macular degeneration, such as injections or laser therapy.
- You do not have other serious eye conditions like high eye pressure or recent bleeding in the study eye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called SMO1 for people with vision loss and swelling in the eye caused by a blocked vein in the retina. It involves regular eye injections to see if the medicine can reduce swelling and improve vision.
This study tests a new medicine given as an eye injection to treat wet age-related macular degeneration (AMD), a condition that causes blurry or lost vision. The treatment aims to improve vision by targeting abnormal blood vessels in the eye.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
Hear when a new Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.